

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 07-9-2007

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 07-7-2007 TO BE PUBLISHED ON 08-9-2007 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

790/2007	<u>02-07-2007</u> 1. Mrs. Hamida Abid Mr. Javed Ali PCSIR Laboratories Peshawar Pakistan	“ Process for the production of carrots powder”
791/2007	N.V. Organon, Netherlands (Priority 04-7-06 Europe)	“Heterocyclic derivatives”
792/2007	Merck Co. Inc USA (Priority 10-7-06 USA)	“Tyrosine kinase inhibitors”
793/2007	<u>03-7-2007</u> Pfizer Products Inc. USA (Priority 05-7-06 USA)	“Therapeutic compounds”
794/2007	1.Syngenta Participations AG, Switzerland 2. Syngenta Limited United Kingdom (Priority 21-7-06 UK)	“ Chemical compounds”
795/2007	AstraZeneca AB, Sweden (Priority 12-7-06 USA)	“New compounds 1/418”
796/2007	Glaxo Group Limited. United Kingdom (Priority 06-7-06 GB)	“Novel receptor antagonists and their methods of use”
797/2007	Bayer HealthCare AG, Germany (Priority 06-7-06 Germany)	“Aqueous pharmaceutical formulation of 4-[(4-carboxybutyl)-{[(4-phenethylbenzyl)oxy]-phenethyl} methyl]benzoic acid”
798/2007	<u>04-7-2007</u> Syngenta Limited, United Kingdom (Priority 20-7-06 UK)	“Herbicidal compounds”
799/2007	Janssen Pharmaceutica N.V. Belgium Divisional	“A process for preparing polyarylcaboxamide useful as lipid lowering agent”
800/2007	REVO PTY Limited,	“Method and system for providing betting of

	Australia (Priority 04-7-06 Australia)	wagering on a sporting event”
801/2007	Phytopharm plc. United Kingdom (Priority 06-7-06 UK)	“Chemical compounds”
	<u>05-7-2007</u>	
802/2007	Sandwich Panel Construction SDN BHD Malaysia	“Improved prefabricated wall panel and the method of manufacture”
803/2007	Arena Pharmaceuticals, Inc. USA (Priority 06-7-06 US)	“Modulators of metabolism and the treatment of disorders related thereto”
804/2007	Arena Pharmaceuticals, Inc. USA (Priority 06-7-06 US)	“Modulators of metabolism and the treatment of disorders related thereto”
805/2007	Boehringer Ingelheim International GmbH, Germany (Priority 07-7-06 Europe)	“New chemical compounds”
806/2007	F. Hoffmann-La Roche AG, Switzerland Divisional	“A process for the manufacture of novel sulfonylaminopyrimidine compound”
	<u>06-7-2007</u>	
807/2007	Pfizer Products Inc. USA (Priority 06-7-06 USA)	“Selective azole PDE10A inhibitor compounds”
808/2007	1. Bayer Schring Pharma Aktiengesellschaft Germany 2. AstraZeneca AB, Sweden (Priority 14-7-06 EP)	“Benzyl amines, a process for their production and their use as anti-inflammatory agents”
809/2007	F. Hoffmann-La Roche AG, Switzerland Divisional	“A method for producing a physiologically active polyethylene glycol (PEG)-interferon (IFN) a conjugate”
810/2007	Janssen Pharmaceutica N.V. Belgium (Priority 11-7-06 USA)	“Benzofuro-and benzothienopyrimidine modulators of the histamine H4 receptor”
811/2007	Bristol-Myers Squibb Company, USA (Priority 06-7-06 USA)	“Novel glucokinase activators and methods of using same”

812/2007	Eli Lilly and Company USA (Priority 05-9-96 US) Divisional	“Selective β 3 adrenergic agonists”
813/2007	Eli Lilly and Company USA (Priority 05-9-96 US) Divisional	“Selective β 3 adrenergic agonists”
814/2007	Australian Sustainable Energy Corporation Pty Ltd. Australia (Priority 11-7-06 Australia)	“Wave energy converter”
815/2007	<u>07-7-2007</u> Mr. Mohammad Yasin Khan PCSIR Karachi Pakistan	“Khan’s solar oven”
816/2007	Avanir Pharmaceuticals USA (Priority 24-5-01 USA) Divisional	“Substituted quinoline derivative as inhibitor of macrophage migration inhibitory factor”
817/2007	Sanofi-Aventis France (Priority 03-8-06 France)	“Pyrazolo[4,3-d]thiazole derivatives, reparation thereof and therapeutic use thereof”
818/2007	Sanofi-Aventis France (Priority 18-7-06 Europe)	“Antagonist antibody for the treatment of cancer”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


937/2003 Pfizer Products Inc
USA

“ Purine compound”

(CO7D 473/16)

139284

Compound of formula (1) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals



SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139281	Chiesi Pharmaceutici SPA Italy	687/2002
139282	Bayer Pharmaceuticals Corporation USA	663/2003
139283	Dressel Pte. Ltd. Singapore.	1243/2005

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Tel: 9215488